Skip to main content

Fiscal Wizard · Single-issue tearsheet

CTSO / Jun 22, 2026 Run #7647

CTSO

Cytosorbents Corporation

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Composite verdict

F 25.1 / 100
Bearish setup · Reversal 10 drivers · 8 gates blocking
  • Rate of Change
  • Chaikin Money Flow
  • Accumulation/Distribution Line
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 62nd of 141 in Medical Devices

rescore-sweep
Technical synthesisRegime: volatile downtrend
Bull 0%Evidence: High · 17 signals100% Bear
Momentum Bearish 4Mean-reversion Neutral 48
  • Late-stage trendTrend signals have been live for 67 bars — past the ~60-bar window; momentum edge decays and can reverse late in a move. (medium confidence)
Where value comes fromMargin of safety -94%

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Mixed

50.1 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
Revenue Growth (YoY) 100
Free Cash Flow Yield 0
Capex to Sales 75
Inventory Turnover 0

Technicals Bearish

0.1 / 100

Bearish setup leads (Rate of Change, Chaikin Money Flow, Accumulation/Distribution Line); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 5
Chaikin Money Flow 11
Accumulation/Distribution Line 11

Risk Gates

8 blocking 3 caution

8 guards active, 23 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Beneish M-Score Blocking

Bottom-band Beneish M blocks bullish signals — accounting-quality risk.

Debt-to-Equity Blocking

High debt-to-equity blocks bullish signals — leverage risk.

LT Debt-to-Equity Blocking

High long-term D/E blocks bullish signals — structural-leverage risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for CTSO.